Holen Sie sich die Stockscreener-App
3.67
6.69%
0.23
Handel nachbörslich:
3.67
Schlusskurs vom Vortag:
$3.44
Offen:
$3.52
24-Stunden-Volumen:
705.56K
Relative Volume:
1.44
Marktkapitalisierung:
$306.46M
Einnahmen:
$69.56M
Nettoeinkommen (Verlust:
$-240.05M
KGV:
-1.2441
EPS:
-2.95
Netto-Cashflow:
$-121.90M
1W Leistung:
+18.77%
1M Leistung:
+184.50%
6M Leistung:
+17.25%
1J Leistung:
+5.46%
1-Tages-Spanne:
$3.441
$3.745
1-Wochen-Bereich:
$2.88
$3.85
52-Wochen-Spanne:
$1.05
$4.13
Adc Therapeutics Sa Stock (ADCT) Company Profile
Firmenname
Adc Therapeutics Sa
Sektor
Branche
Telefon
41 21 653 02 00
Adresse
BIOPOLE, EPALINGES
Vergleichen Sie ADCT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADCT
Adc Therapeutics Sa
|
3.67 | 306.46M | 69.56M | -240.05M | -121.90M | -2.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-08 | Eingeleitet | Stephens | Overweight |
| 2024-05-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-03-28 | Eingeleitet | Guggenheim | Buy |
| 2023-08-10 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-04-24 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-12-06 | Eingeleitet | CapitalOne | Overweight |
| 2022-11-09 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-09-21 | Eingeleitet | JP Morgan | Overweight |
| 2022-09-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-09 | Eingeleitet | Wolfe Research | Outperform |
| 2021-08-17 | Fortgesetzt | Jefferies | Buy |
| 2021-08-09 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-06-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-12-03 | Eingeleitet | Stifel | Hold |
| 2020-10-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-06-09 | Eingeleitet | BofA/Merrill | Buy |
| 2020-06-09 | Eingeleitet | Cowen | Outperform |
Alle ansehen
Adc Therapeutics Sa Aktie (ADCT) Neueste Nachrichten
Nuveen Asset Management LLC Purchases 22,989 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics Approves Key Proposals at Annual Meeting - TipRanks
ProShare Advisors LLC Increases Position in ADC Therapeutics SA (NYSE:ADCT) - Defense World
Bank of America Corp DE Sells 1,206,696 Shares of ADC Therapeutics SA (NYSE:ADCT) - MarketBeat
Adc Therapeutics SA (NYSE: ADCT) Jumps 2.28%, Turning Investors Away - Stocksregister
ADC Therapeutics SA (NYSE:ADCT) Stock Position Boosted by Deutsche Bank AG - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Boosts Stock Position in ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Pioneer Awards Strategic Stock Options Package to Secure Top Industry Talent - Stock Titan
Bank of America Corp DE Has $2.57 Million Position in ADC Therapeutics SA (NYSE:ADCT) - Defense World
Astellas and Evopoint sign ADC licensing deal - Pharmaceutical Technology
Woodline Partners LP Takes Position in ADC Therapeutics SA (NYSE:ADCT) - MarketBeat
Shareholders Will Likely Find ADC Therapeutics SA's (NYSE:ADCT) CEO Compensation Acceptable - simplywall.st
BNP Paribas Financial Markets Takes $1.43 Million Position in ADC Therapeutics SA (NYSE:ADCT) - MarketBeat
Equities Analysts Set Expectations for ADCT FY2025 Earnings - MarketBeat
Antibody Drug Conjugates Market will reach 11.5 Billion USD by 2032 - newstrail.com
ADC Therapeutics signals data catalysts ahead with ZYNLONTA combinations, aims for regulatory milestones through 2025 - MSN
BNP Paribas Financial Markets Purchases Shares of 716,668 ADC Therapeutics SA (NYSE:ADCT) - Defense World
FY2025 EPS Estimates for ADCT Increased by Cantor Fitzgerald - Defense World
Orbimed Advisors LLC Acquires 1,434,650 Shares of ADC Therapeutics SA (NYSE:ADCT) - MarketBeat
ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update - Nasdaq
Analysts Are Upgrading ADC Therapeutics SA (NYSE:ADCT) After Its Latest Results - simplywall.st
Royal Bank of Canada Reaffirms “Outperform” Rating for ADC Therapeutics (NYSE:ADCT) - Defense World
ADC Therapeutics patents new anti-NaPi2b conjugates - BioWorld MedTech
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Tops Revenue Estimates - MSN
ADC Therapeutics (ADCT) Receives Reiterated Outperform Rating fr - GuruFocus
ADC Therapeutics presents new anti-ASCT2 conjugates - BioWorld MedTech
ADC Therapeutics SA (NYSE:ADCT) Q1 2025 Earnings Call Transcript - MSN
ADC Therapeutics to Present at Upcoming Investor Conferences - GuruFocus
ADCT Reveals Promising LOTIS-7 Trial Data for ZYNLONTA | ADCT St - GuruFocus
ADC Therapeutics ends development of ADCT-602 and unveils latest Zynlonta data - Clinical Trials Arena
ADC Therapeutics reports high response in lymphoma trial By Investing.com - Investing.com Canada
ADC Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat
ADCT stock touches 52-week low at $1.66 amid market challenges - MSN
ADC Therapeutics stock plunges 36% amid Zynlonta data release - MSN
ADC Therapeutics SA 2025 Q1ResultsEarnings Call Presentation (NYSE:ADCT) - Seeking Alpha
ADC Therapeutics SA reports results for the quarter ended March 31Earnings Summary - TradingView
Transcript : ADC Therapeutics SA, Q1 2025 Earnings Call, May 14, 2025 - marketscreener.com
ADC Therapeutics Reports First Quarter 2025 Financial Results - TradingView
ADC Therapeutics Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML) - GuruFocus
ADC Therapeutics reports high response in lymphoma trial - Investing.com
ADC Therapeutics Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML) – Company AnnouncementFT.com - Financial Times
What To Expect From ADC Therapeutics SA (ADCT) Q1 2025 Earnings - GuruFocus
Wells Fargo & Company MN Increases Stock Holdings in ADC Therapeutics SA (NYSE:ADCT) - Defense World
Blood Cancer Treatment Market Sees Accelerated Growth Across the 7MM Amid Rising Incidence and Breakthroughs | DelveInsight - GlobeNewswire Inc.
Barclays PLC Purchases 13,756 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World
Finanzdaten der Adc Therapeutics Sa-Aktie (ADCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.21%
1.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):